Current Status of COVID-19 Therapies and Drug Repositioning Applications

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · see citing works

Clinical characteristics of coronavirus disease 2019 in China

Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246 · see citing works

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · see citing works

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works

Epidemiological and clinical characteristics of 99 cases of 2019 novel Coronavirus pneumonia in Wuhan, China: a descriptive study.

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415 · see citing works

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907 · see citing works

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Chan, J., Yuan, S.-F., Kok, K.-H., To, K., Chu, H., Yang, J., Xing, F., Liu, J.-L., Yip, C., Poon, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,450 · see citing works

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,436 · see citing works

Remdesivir for the Treatment of Covid-19 — Final Report

Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267 · see citing works

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,967 · see citing works

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · see citing works

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187 · see citing works

Drug repurposing: progress, challenges and recommendations

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718 · see citing works

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Zou, L., Ruan, F., Huang, M.-X., Liang, L.-J., Huang, H., Hong, Z.-S., Yu, J.-X., Kang, M., Song, Y.-C., Xia, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001737 · Cited by 4,590 · see citing works

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,432 · see citing works

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405 · see citing works

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Li, C., Ai, Q., Lu, W., Liang, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30096-6 · Cited by 4,384 · see citing works

Docking and scoring in virtual screening for drug discovery: methods and applications

Kitchen, D. B., Decornez, H. Y., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,245 · see citing works

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171 · see citing works

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

Rothe, C., Schunk, M., Sothmann, P., Bretzel, G., Froeschl, G., Wallrauch, C., Zimmer, T., Thiel, V., Jänke, C., Guggemos, W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001468 · Cited by 4,143 · see citing works

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury

Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445 · see citing works

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,442 · see citing works

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 3,275 · see citing works

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Liu, Y., Gayle, A. A., Wilder‐Smith, A., & Rocklöv, J. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa021 · Cited by 3,169 · see citing works

Bats Are Natural Reservoirs of SARS-Like Coronaviruses

Li, W., Shi, Z., Yu, M., Ren, W., Smith, C. S., Epstein, J. H., Wang, H., Crameri, G. S., Hú, Z., Zhang, H., et al. (2005) · Science · doi:10.1126/science.1118391 · Cited by 2,571 · see citing works

Clinical development success rates for investigational drugs

Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · see citing works

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,357 · see citing works

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,278 · see citing works

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Zhang, Y., Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., Chen, H., Ding, X., Zhao, H., Zhang, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2007575 · Cited by 2,179 · see citing works

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122 · see citing works

Predicting new molecular targets for known drugs

Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667 · see citing works

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · cited 1× · see citing works

On the origin and continuing evolution of SARS-CoV-2

Tang, X., Wu, C., Li, X., Song, Y., Yao, X., Wu, X., Duan, Y., Zhang, H., Wang, Y., Qian, Z., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa036 · Cited by 1,593 · see citing works

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures

Wang, Y., Wang, Y., Chen, Y., & Qin, Q. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25748 · Cited by 1,521 · see citing works

Approved Antiviral Drugs over the Past 50 Years

Clercq, E. D., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,443 · see citing works

Severe acute respiratory syndrome-related coronavirus : The species and its viruses – a statement of the Coronavirus Study GroupPreprint

Gorbalenya, A. E., Baker, S. C., Baric, R. S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.07.937862 · Cited by 1,408 · see citing works

Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study

Giacomelli, A., Pezzati, L., Conti, F., Bernacchia, D., Siano, M., Oreni, L., Rusconi, S., Gervasoni, C., Ridolfo, A. L., Rizzardini, G., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa330 · Cited by 1,326 · see citing works

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266 · see citing works

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.03.005 · Cited by 1,158 · see citing works

COVID-19: combining antiviral and anti-inflammatory treatments

Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117 · see citing works

Host-directed therapies for bacterial and viral infections

Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. F. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 847 · see citing works

A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period

Yu, P., Jiang, Z., Zhang, Z., & Han, Y. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa077 · Cited by 655 · see citing works

Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen

Xu, M., Lee, E. M., Wen, Z., Cheng, Y., Huang, W.-K., Qian, X., Julia, T. C. W., Kouznetsova, J., Ogden, S. C., Hammack, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4184 · Cited by 642 · see citing works

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Tchesnokov, E. P., Feng, J. Y., Porter, D., & Götte, M. (2019) · Viruses · doi:10.3390/v11040326 · Cited by 623 · see citing works

A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

Ratia, K. M., Pegan, S. D., Takayama, J., Sleeman, K., Coughlin, M. M., Baliji, S., Chaudhuri, R., Fu, W., Prabhakar, B. S., Johnson, M. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805240105 · Cited by 517 · see citing works

Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China

Tang, A., Tong, Z.-D., Wang, H.-L., Dai, Y.-X., Li, K.-F., Liu, J.-N., Wu, W.-J., Yuan, C., Yu, M.-L., Li, P., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2606.200301 · Cited by 516 · see citing works

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design

Xue, X., Yu, H. D., Yang, H., Xue, F., Wu, Z., Shen, W., Li, J., Zhou, Z., Ding, Y., Zhao, Q., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02114-07 · Cited by 472 · see citing works

Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients

Bost, P., Giladi, A., Liu, Y., Bendjelal, Y., Xu, G., David, E., Blecher-Gonen, R., Cohen, M., Medaglia, C., Li, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.006 · Cited by 471 · see citing works

Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2

Bao, L., Deng, W., Gao, H., Xiao, C., Liu, J., Xue, J., Lv, Q., Liu, J., Yu, P., Xu, Y., et al. (2020) · doi:10.1101/2020.03.13.990226 · Cited by 419 · see citing works

Use of genome-wide association studies for drug repositioning

Sanséau, P., Agarwal, P., Barnes, M. R., Pastinen, T., Richards, J. B., Cardon, L. R., & Mooser, V. (2012) · Nature Biotechnology · doi:10.1038/nbt.2151 · Cited by 387 · see citing works

Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study GroupPreprint

Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., et al. (2020) · DIGITAL.CSIC (Spanish National Research Council (CSIC)) · doi:10.1101/2020.02.07.937862v1 · Cited by 382 · see citing works

Ongoing Clinical Trials for the Management of the COVID-19 Pandemic

Lythgoe, M. P., & Middleton, P. K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.006 · Cited by 380 · see citing works

Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity

Chen, W., Lan, Y., Yuan, X.-Z., Deng, X., Li, Y., Cai, X., Li, L., He, R., Tan, Y., Deng, X., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1732837 · Cited by 378 · see citing works

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Patel, A. B., & Verma, A. (2020) · JAMA · doi:10.1001/jama.2020.4812 · Cited by 378 · see citing works

In silicopharmacology for drug discovery: applications to targets and beyond

Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707306 · Cited by 367 · see citing works

Drug repurposing from an academic perspective

Oprea, T. I., Bauman, J. E., Bologa, C., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B. L., et al. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.002 · Cited by 364 · see citing works

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

Kotch, C., Barrett, D. M., & Teachey, D. T. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1629904 · Cited by 322 · see citing works

Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond

Boldescu, V., Behnam, M. A. M., Vasilakis, N., & Klein, C. D. P. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.33 · Cited by 309 · see citing works

A second, non‐canonical RNA‐dependent RNA polymerase in SARS Coronavirus

Imbert, I., Guillemot, J., Bourhis, J., Bussetta, C., Coutard, B., Egloff, M. P., Ferrón, F., Gorbalenya, A. E., & Canard, B. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601368 · Cited by 277 · see citing works

Potent human neutralizing antibodies elicited by SARS-CoV-2 infectionPreprint

Ju, B., Zhang, Q., Ge, X., et al. (2020) · bioRxiv · doi:10.1101/2020.03.21.990770 · Cited by 256 · see citing works

Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines

Müller, M. A., Raj, V. S., Muth, D., Meyer, B., Kallies, S., Smits, S. L., Wollny, R., Bestebroer, T. M., Specht, S., Suliman, T., et al. (2012) · mBio · doi:10.1128/mbio.00515-12 · Cited by 206 · see citing works

Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring

Xiao, S., Wu, Y., & Liu, H. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25702 · Cited by 206 · see citing works

Pneumonic Plague: The Darker Side of Yersinia pestis

Pechous, R. D., Sivaraman, V., Stasulli, N. M., & Goldman, W. E. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.11.008 · Cited by 148 · see citing works

Assessing Activity and Inhibition of Middle East Respiratory Syndrome Coronavirus Papain-Like and 3C-Like Proteases Using Luciferase-Based Biosensors

Kilianski, A., Mielech, A. M., Deng, X., & Baker, S. C. (2013) · Journal of Virology · doi:10.1128/jvi.02105-13 · Cited by 142 · see citing works

Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy

Pizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00531 · Cited by 122 · cited 1× · see citing works

Single-cell metagenomics: challenges and applications

Xu, Y., & Zhao, F. (2018) · Protein & Cell · doi:10.1007/s13238-018-0544-5 · Cited by 115 · see citing works

Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning

Turanlı, B., Zhang, C., Kim, W., Benfeitas, R., Uhlén, M., Arğa, K. Y., & Mardinoğlu, A. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.009 · Cited by 91 · see citing works

Drug repurposing: a better approach for infectious disease drug discovery?

Law, G. L., Tisoncik-Go, J., Korth, M. J., & Katze, M. G. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.08.004 · Cited by 90 · see citing works

Systems biology based drug repositioning for development of cancer therapy

Turanlı, B., Altay, Ö., Borén, J., Türkez, H., Nielsen, J., Uhlén, M., Arğa, K. Y., & Mardinoğlu, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.020 · Cited by 80 · see citing works

Renovation as innovation: is repurposing the future of drug discovery research?

Neuberger, A., Oraiopoulos, N., & Drakeman, D. L. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.06.012 · Cited by 76 · see citing works

A review of the 1918 herald pandemic wave: importance for contemporary pandemic response strategies

Simonsen, L., Chowell, G., Andreasen, V., Gaffey, R., Barry, J., Olson, D. R., & Viboud, C. G. (2018) · Annals of Epidemiology · doi:10.1016/j.annepidem.2018.02.013 · Cited by 73 · see citing works

A review of validation strategies for computational drug repositioning

Brown, A. S., & Patel, C. J. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw110 · Cited by 68 · see citing works

Historical Parallels, Ebola Virus Disease and Cholera: Understanding Community Distrust and Social Violence with Epidemics

Cohn, S. K., & Kutalek, R. (2016) · PLoS Currents · doi:10.1371/currents.outbreaks.aa1f2b60e8d43939b43fbd93e1a63a94 · Cited by 60 · see citing works

Pathway and network-based strategies to translate genetic discoveries into effective therapies

Greene, C. S., & Voight, B. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw160 · Cited by 49 · see citing works

Multiscale modelling of drug mechanism and safety

Zhang, J. D., Sach-Peltason, L., Krämer, C., Wang, K., & Ebeling, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.009 · Cited by 22 · see citing works

Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients

Pottecher, J., Noll, É., Borel, M., Audibert, G., Gette, S., Meyer, C., Gaertner, É., Legros, V., Carapito, R., Uring‐Lambert, B., et al. (2020) · Trials · doi:10.1186/s13063-020-4141-6 · Cited by 16 · see citing works

A prospective, randomized, single-blind, multicentre, phase III study on organ preservation with Custodiol-N solution compared with Custodiol® solution in organ transplantation (kidney, liver and pancreas)

Kniepeiss, D., Houben, P., Stiegler, P., Berghold, A., Riedl, R., Kahn, J., & Schemmer, P. (2020) · Trials · doi:10.1186/s13063-019-3823-4 · Cited by 15 · see citing works

Remdesivir for the Treatment of Covid-19 — Final Report

Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267 · see citing works

Drug repurposing for COVID-19 via knowledge graph completion

Zhang, R., Hristovski, D., Schutte, D., Kastrin, A., Marcelo Fiszman, B., & Halil Kilicoglu, B. (2021) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2021.103696 · Cited by 224 · see citing works

Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants

Guedes, I. A., Costa, L. S. C., Santos, K. B., Karl, A. L. M., Rocha, G. K., Teixeira, I. M., Galheigo, M. M., Medeiros, V., Krempser, E., Custódio, F. L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84700-0 · Cited by 153 · see citing works

Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19

Altay, O., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G., Kim, W., Akyol, D., Zhang, C., Dinler‐Doganay, G., et al. (2021) · Advanced Science · doi:10.1002/advs.202101222 · Cited by 88 · see citing works

Carvacrol, a Plant Metabolite Targeting Viral Protease (Mpro) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19

Javed, H., Meeran, M. F. N., Jha, N. K., & Ojha, S. K. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2020.601335 · Cited by 84 · see citing works

A global picture: therapeutic perspectives for COVID-19

Chavda, V., Kapadia, C., Soni, S., Prajapati, R., Chauhan, S., Yallapu, M., & Apostolopoulos, V. (2022) · Immunotherapy · doi:10.2217/imt-2021-0168 · Cited by 66 · see citing works

Mesenchymal stem cell immunomodulation: in pursuit of controlling COVID-19 related cytokine storm

Song, N., Wakimoto, H., Rossignoli, F., Bhere, D., Ciccocioppo, R., Chen, K.-S., Khalsa, J. K., Mastrolia, I., Samarelli, A. V., Dominici, M., et al. (2021) · Stem Cells · doi:10.1002/stem.3354 · Cited by 62 · see citing works

Computational and Experimental Studies Reveal That Thymoquinone Blocks the Entry of Coronaviruses Into In Vitro Cells

Xu, H., Liu, B., Xiao, Z., Zhou, M., Ge, L., Jia, F., Liu, Y., Jin, H., Zhu, X., Gao, J., et al. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00400-2 · Cited by 59 · see citing works

Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study

Iwanami, S., Ejima, K., Kim, K. S., Noshita, K., Fujita, Y., Miyazaki, T., Kohno, S., Miyazaki, Y., Morimoto, S., Nakaoka, S., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003660 · Cited by 59 · see citing works

Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 Mpro Protease

Tejera, E., Munteanu, C. R., López‐Cortés, A., Cabrera‐Andrade, A., & Pérez‐Castillo, Y. (2020) · Molecules · doi:10.3390/molecules25215172 · Cited by 55 · see citing works

Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications

Caldara, M., & Marmiroli, N. (2021) · Pharmaceuticals · doi:10.3390/ph14090915 · Cited by 54 · see citing works

Modelling the DFT structural and reactivity study of feverfew and evaluation of its potential antiviral activity against COVID-19 using molecular docking and MD simulations

Lakhera, S., Devlal, K., Ghosh, A., Chowdhury, P., & Rana, M. M. (2022) · Chemical Papers · doi:10.1007/s11696-022-02067-6 · Cited by 52 · see citing works

Trends of Artificial Intelligence (AI) Use in Drug Targets, Discovery and Development: Current Status and Future Perspectives

Mohapatra, M., Sahu, C., & Mohapatra, S. (2024) · Current Drug Targets · doi:10.2174/0113894501322734241008163304 · Cited by 52 · see citing works

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval

Ashour, N. A., Elmaaty, A. A., Sarhan, A. A., Elkaeed, E. B., Moussa, A. M., Erfan, I. A., & Al-Karmalawy, A. A. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s354841 · Cited by 50 · see citing works

The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic

Won, J., & Lee, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249775 · Cited by 48 · see citing works

Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19?

Meeran, M. F. N., Arunachalam, S., Javed, H., Sharma, C., Hashiesh, H. M., Goyal, S. N., Jha, N. K., & Ojha, S. K. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05703 · Cited by 46 · see citing works

The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies

Waman, V., Sen, N., Váradi, M., Daina, A., Wodak, S. J., Zoete, V., Velankar, S. S., & Orengo, C. A. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa362 · Cited by 46 · see citing works

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval

Ashour, N. A., Abo Elmaaty, A., Sarhan, A. A., Elkaeed, E. B., Moussa, A. M., Erfan, I. A., & Al-Karmalawy, A. A. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 44 · see citing works

Engineering photonics solutions for COVID-19

Soler, M., Scholtz, A., Zeto, R., & Armani, A. M. (2020) · APL Photonics · doi:10.1063/5.0021270 · Cited by 38 · see citing works

Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach

Li, X., Shong, K. E., Kim, W., Yuan, M., Yang, H., Sato, Y., Kume, H., Ogawa, S., Türkez, H., Shoaie, S., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103963 · Cited by 38 · see citing works

The journey of antimalarial drugs against SARS-CoV-2: Review article

Sarhan, A. A., Ashour, N. A., & Al-Karmalawy, A. A. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100604 · Cited by 37 · see citing works

Impact of computational approaches in the fight against COVID-19: an AI guided review of 17 000 studies

Napolitano, F., Xu, X., & Gao, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab456 · Cited by 37 · see citing works

GCNGAT: Drug–disease association prediction based on graph convolution neural network and graph attention network

Yang, R., Fu, Y., Zhang, Q., & Zhang, L. (2024) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2024.102805 · Cited by 34 · see citing works

PROMISCUOUS 2.0: a resource for drug-repositioning

Gallo, K., Goede, A., Eckert, A. P., Moahamed, B., Preißner, R., & Gohlke, B.-O. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1061 · Cited by 34 · see citing works

Integrated network analysis reveals new genes suggesting COVID-19 chronic effects and treatment

Pavel, A., del Giudice, G., Federico, A., Lieto, A. D., Kinaret, P., Serra, A., & Greco, D. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa417 · Cited by 33 · see citing works

Serratiopeptidase, A Serine Protease Anti-Inflammatory, Fibrinolytic, and Mucolytic Drug, Can Be a Useful Adjuvant for Management in COVID-19

Sharma, C., Jha, N. K., Meeran, M. F. N., Patil, C. R., Goyal, S. N., & Ojha, S. K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.603997 · Cited by 32 · see citing works

CB2 receptor‐selective agonists as candidates for targeting infection, inflammation, and immunity in SARS‐CoV ‐2 infections

Meeran, M. F. N., Sharma, C., Goyal, S. N., Kumar, S., & Ojha, S. K. (2020) · Drug Development Research · doi:10.1002/ddr.21752 · Cited by 30 · see citing works

Ecotoxicity and genotoxicity assessment of losartan after UV/H2O2 and UVC/photolysis treatments

Adams, E., Neves, B. B., Prola, L. D. T., de Liz, M. V., Martins, L. R. R., Ramsdorf, W. A., & de Freitas, A. M. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-11420-9 · Cited by 29 · see citing works

Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M pro

Balaramnavar, V. M., Ahmad, K., Saeed, M., Ahmad, I. S., Kamal, M., & Jawed, T. (2020) · RSC Advances · doi:10.1039/d0ra06038k · Cited by 29 · see citing works

Prospecting for Cressa cretica to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2

Shah, S., Chaple, D., Arora, S., Yende, S. R., Mehta, C. H., & Nayak, U. Y. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1872419 · Cited by 26 · see citing works

Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns

Mslati, H., Gentile, F., Perez, C. F., & Cherkasov, A. R. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00384 · Cited by 26 · see citing works

Applications of Genome-Wide Screening and Systems Biology Approaches in Drug Repositioning

Mohammadi, E., Benfeitas, R., Türkez, H., Borén, J., Nielsen, J., Uhlén, M., & Mardinoğlu, A. (2020) · Cancers · doi:10.3390/cancers12092694 · Cited by 25 · see citing works

A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives

Sezer, A., Halilović-Alihodžić, M., Vanwieren, A. R., Smajkan, A., Karić, A., Djedović, H., & Šutković, J. (2022) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-022-00353-0 · Cited by 25 · see citing works

Network for network concept offers new insights into host- SARS-CoV-2 protein interactions and potential novel targets for developing antiviral drugs

Eskandarzade, N., Ghorbani, A., Samarfard, S., Dı́az, J., Guzzi, P. H., Fariborzi, N., Tahmasebi, A., & Izadpanah, K. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105575 · Cited by 22 · see citing works

Inclusion complexation of chloroquine with α and β-cyclodextrin: Theoretical insights from the new B97-3c composite method

Assaba, I. M., Rahali, S., Belhocine, Y., & Allal, H. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129696 · Cited by 23 · see citing works

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies

Barghash, R. F., Gemmati, D., Awad, A. M., Elbakry, M. M. M., Tisato, V., Awad, K., & Singh, A. V. (2024) · Molecules · doi:10.3390/molecules29235564 · Cited by 23 · see citing works

A computational framework of host-based drug repositioning for broad-spectrum antivirals against RNA viruses

Li, Z., Yao, Y., Cheng, X., Chen, Q., Zhao, W., Ma, S., Li, Z., Zhou, H., Li, W., & Teng, F. (2021) · iScience · doi:10.1016/j.isci.2021.102148 · Cited by 21 · see citing works

Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation

Serra, A., Fratello, M., Federico, A., Ojha, R., Provenzani, R., Tasnádi, E., Cattelani, L., del Giudice, G., Kinaret, P., Saarimäki, L. A., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab507 · Cited by 21 · see citing works

Technical Data of Heterologous Expression and Purification of SARS-CoV-2 Proteases Using Escherichia coli System

Razali, R., Subbiah, V. K., & Budiman, C. (2021) · Data · doi:10.3390/data6090099 · Cited by 18 · see citing works

Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?

Kirkham, A. M., Bailey, A. J.-M., Shorr, R., Lalu, M. M., Fergusson, D. A., & Allan, D. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.10.003 · Cited by 18 · see citing works

Fighting COVID-19 with Artificial Intelligence

Monteleone, S., Kellici, T. F., Southey, M., Bodkin, M. J., & Heifetz, A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_3 · Cited by 17 · see citing works

In silico approaches for drug repurposing in oncology: a scoping review

Cavalcante, B. R. R., Freitas, R. D., da Rocha, L. D. O. S., dos Santos, R. D. S. B., Souza, B. S. D. F., Ramos, P. I. P., Rocha, G. V., & Rocha, C. A. G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1400029 · Cited by 17 · see citing works

Identifying the Hot Spot Residues of the SARS-CoV-2 Main Protease Using MM-PBSA and Multiple Force Fields

Byun, J., & Lee, J. (2021) · Life · doi:10.3390/life12010054 · Cited by 17 · see citing works

Coalescence of co-infection and antimicrobial resistance with SARS-CoV-2 infection: The blues of post-COVID-19 world

Mazumder, P., Kalamdhad, A. S., Chaminda, T., & Kumar, M. (2021) · Case Studies in Chemical and Environmental Engineering · doi:10.1016/j.cscee.2021.100093 · Cited by 16 · see citing works

Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19

Dey, M., & Singh, R. K. (2021) · Pharmacology · doi:10.1159/000518359 · Cited by 16 · see citing works

Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning

Li, X., Kim, W., Juszczak, K., Arif, M., Sato, Y., Kume, H., Ogawa, S., Türkez, H., Borén, J., Nielsen, J., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102722 · Cited by 14 · see citing works

RP-HPLC Method Development, Validation, and Drug Repurposing of Sofosbuvir Pharmaceutical Dosage Form: A Multidimensional Study

Mangrio, G. R., Maneengam, A., Khalid, Z., Jafar, T. H., Chanihoon, G. Q., Nassani, R., & Unar, A. (2022) · Environmental Research · doi:10.1016/j.envres.2022.113282 · Cited by 13 · see citing works

Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor

Ahsan, T., & Sajib, A. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.100982 · Cited by 13 · see citing works

Live and let die: signaling AKTivation and UPRegulation dynamics in SARS-CoVs infection and cancer

Suaya, M., Sanchez, G. M., Vila, A., Amante, A., Cotarelo, M., Carrillo, M. G., & Blaustein, M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05250-5 · Cited by 12 · see citing works

Drug repositioning for immunotherapy in breast cancer using single-cell analysis

Mohammadi, E., Dashti, S., Shafizade, N., Jin, H., Zhang, C., Lam, S., Tahmoorespur, M., Mardinoğlu, A., & Sekhavati, M. H. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00359-z · Cited by 10 · see citing works

Survey of network-based approaches of drug-target interaction prediction

Jung, L. S., & Cho, Y. (2020) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm49941.2020.9313222 · Cited by 10 · see citing works

Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19

Rasouli, M., Vakilian, F., & Ranjbari, J. (2020) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x16666201221151853 · Cited by 9 · see citing works

The potential of BEN815 as an anti-inflammatory, antiviral and antioxidant agent for the treatment of COVID-19

Shin, J. A., Oh, S., & Jeong, J. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100058 · Cited by 9 · see citing works

Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches

Mukherjee, A., Verma, A., Bihani, S., Burli, A., Mantri, K., & Srivastava, S. (2021) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2021.06.004 · Cited by 9 · see citing works

Genome-scale metabolic models in translational medicine: the current status and potential of machine learning in improving the effectiveness of the models

Turanlı, B., Gülfidan, G., Aydogan, O. O., Kula, C., Selvaraj, G., & Arğa, K. Y. (2024) · Molecular Omics · doi:10.1039/d3mo00152k · Cited by 9 · see citing works

Can sulfasalazine as an old drug with immunomodulatory and anti‐inflammatory effects be effective in COVID‐19?

Ghasemnejad‐Berenji, M. (2021) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2021-0349 · Cited by 8 · see citing works

Can Anti-Parasitic Drugs Help Control COVID-19?

Panahi, Y., Dadkhah, M., Talei, S., Gharari, Z., Asghariazar, V., Abdolmaleki, A., Matin, S., & Molaei, S. (2022) · Future Virology · doi:10.2217/fvl-2021-0160 · Cited by 8 · see citing works

Cheminformatics and Bioinformatics at the Interface with Systems Biology

Kaushik, A. C., Mehmood, A., Wei, D., Nawab, S., Sahi, S., & Kumar, A. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166037 · Cited by 7 · see citing works

Efficacy and Safety of Antimalarial as Repurposing Drug for COVID-19 Following Retraction of Chloroquine and Hydroxychloroquine

Latarissa, I. R., Khairinisa, M. A., Iftinan, G. N., Meiliana, A., Sormin, I. P., Barliana, M. I., & Lestari, K. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s493750 · Cited by 7 · see citing works

New synthetic corticosteroids inhibit Epstein–Barr virus release

Malykh, A., Pavlov, A. R., Komkov, A. V., Volkova, Y. A., Menchikov, L. G., & Zavarzin, I. V. (2021) · Mendeleev Communications · doi:10.1016/j.mencom.2021.09.025 · Cited by 6 · see citing works

Interactome-Based Machine Learning Predicts Potential Therapeutics for COVID-19

Ghosh, N., Saha, I., & Gambin, A. (2023) · ACS Omega · doi:10.1021/acsomega.3c00030 · Cited by 6 · see citing works

DETAILED VIEW ON REPURPOSED DRUGS, TRACKING OF VACCINES,AND BRIEF VIEW ON PROPHYLACTIC NANOMEDICINES AS AN ALTERNATIVE APPROACH AND PATIENT CARE FOR COVID-19

Nair, K. S., Kamath, S. R., Rajan, A., Thomas, S. B., Aswin, D., & Zachariah, S. M. (2021) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2021v13i1.39705 · Cited by 5 · see citing works

Improvement of the performance of anticancer peptides using a drug repositioning pipeline

Mohammadi, E., Tahmoorespur, M., Benfeitas, R., Altay, Ö., Javadmanesh, A., Lam, S. C. C., Mardinoğlu, A., & Sekhavati, M. H. (2021) · Biotechnology Journal · doi:10.1002/biot.202100417 · Cited by 5 · see citing works

Inhalable spray-dried dry powders combining ivermectin and niclosamide to inhibit SARS-CoV-2 infection in vitro

Su, C., Saha, T., Sinha, S., Hird, C. P., Smith, S. X. Y., Quiñones‐Mateu, M. E., & Das, S. C. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125302 · Cited by 4 · see citing works

Drug Synergism of Anticancer Action in Combination with Favipiravir and Paclitaxel on Neuroblastoma Cells

Türkez, H., Arslan, M. E., Selvi̇topi̇, H., Kadı, A., Öner, S., & Mardinoğlu, A. (2023) · Medicina · doi:10.3390/medicina60010082 · Cited by 3 · see citing works

Cardiovascular Comorbidities in COVID-19: Comprehensive Analysis of Key Topics

Markovič, R., Ternar, L., Trstenjak, T., Marhl, M., & Grubelnik, V. (2024) · Interactive Journal of Medical Research · doi:10.2196/55699 · Cited by 3 · see citing works

COVID-19 Drug Repositioning: Present Status and Prospects

Mohanty, C., Vinod, C., Acharya, S., & Mahapatra, N. (2021) · Studies in systems, decision and control · doi:10.1007/978-3-030-72834-2_19 · Cited by 3 · see citing works

Plant-derived Antiviral Compounds as Potential COVID-19 Drug Candidates: In-silico Investigation in Search of SARS-CoV-2 Inhibitors

Kolita, B., Borah, D., Hazarika, P., Phukan, E., & Borah, R. R. (2023) · Trends in Sciences · doi:10.48048/tis.2023.5529 · Cited by 3 · see citing works

COVID-19, hydroxychloroquine and the importance of disease progression

Budny, J. A. (2021) · Toxicology Research · doi:10.1093/toxres/tfab015 · Cited by 3 · see citing works

Potential Drugs in COVID-19 Management

Gasmi, A., Noor, S., Menzel, A., Khanyk, N., Semenova, Y., Lysiuk, R., Beley, N. M., Bolibrukh, L., Benahmed, A. G., Storchylo, O. V., et al. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230717154101 · Cited by 3 · see citing works

Are we there yet? Analyzing scientific research related to COVID-19 drug repurposingPreprint

Park, N., Ryu, H., Ding, Y., Yu, Q., Bu, Y., Wang, Q., Yang, J. J., & Song, M. (2020) · Research Square · doi:10.21203/rs.3.rs-80893/v1 · Cited by 3 · see citing works

Bibliometric analysis of the research publications on AYUSH-64 for COVID-19

Singh, S. B., Sisodia, B. S., Mansoria, P., Ahmad, A., & Kumar, A. (2024) · International Journal of Ayurveda Research · doi:10.4103/ijar.ijar_128_24 · Cited by 2 · see citing works

Repurposing, effects, design, and discovery of drugs in systems biology

Amjad, E., & Sokouti, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22326-6.00024-9 · Cited by 2 · see citing works

Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir

Shinada, K., Sato, T., Moriyama, S., Adachi, Y., Shinoda, M., Ota, S., Morikawa, M., Mineshita, M., Matsumura, T., Takahashi, Y., et al. (2022) · Viruses · doi:10.3390/v14040670 · Cited by 2 · see citing works

In Silico Screening of the Phenolic Compound Oleuropein and Its Hydrolysis Product 3-Hydroxytyrosol Against Certain Structural and Non-Structural Proteins of SARS-CoV- 2

Istıflı, E. S. (2021) · Türk Tarım ve Doğa Bilimleri Dergisi · doi:10.30910/turkjans.953603 · Cited by 2 · see citing works

Cannabinoid Type-2 Receptor Agonist, JWH133 May Be a Possible Candidate for Targeting Infection, Inflammation, and Immunity in COVID-19

Jha, N. K., Sharma, C., Meeran, M. F. N., Jha, S. K., Dwivedi, V. D., Gupta, P. K., Dey, A., Kesari, K. K., & Ojha, S. K. (2021) · Immuno · doi:10.3390/immuno1030020 · Cited by 2 · see citing works

Experience with and perceptions of non-prescription anthelmintics for cancer treatments among cancer patients in South Korea: A cross-sectional survey

Song, B., Kim, K. J., & Ki, S. H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275620 · Cited by 1 · see citing works

SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning

Lee, S. Y., Song, M. Y., Lee, Y., & An, J. H. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00869-x · Cited by 2 · see citing works

Combined In Vitro and In Silico Evidence for Neuroprotection by Selected Sodium and Potassium Salts in an H₂O₂‐Induced SH‐SY5Y Neurodegeneration Model

Sevim, Y., Arslan, M. E., Düzgün, Z., Tozlu, Ö. Ö., Öner, S., Kadı, A., & Türkez, H. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70681 · Cited by 1 · see citing works

CHALLENGES AND OPPORTUNITIES WITH DRUG REPURPOSING: AN EMERGING TECHNIQUE IN DRUGS DISCOVERY

Harale, S., Hupare, P., Ghatage, P., Govande, V., Gurav, O., Bandgar, S. A., Patil, S. P., & Gaikwad, D. (2023) · INDIAN DRUGS · doi:10.53879/id.60.11.13058 · Cited by 1 · see citing works

Clinical investigation of COVID-19 prevention and treatment

Kulshrestha, S., Raghav, A., Chadha, R., & Raghav, P. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95545-4.00004-9 · Cited by 1 · see citing works

AI4CoV: Matching COVID-19 Patients to Treatment Options Using Artificial IntelligencePreprint

Hsu, A. I., Yeh, A. S., Chen, S.-L., Yeh, J. J., Lv, D., Hsu, J. Y.-J., & Huang, P. J. (2020) · medRxiv · doi:10.1101/2020.11.29.20240614

Modeling and simulation in medical sciences: an overview of specific applications based on research experience in EMRI (Endocrinology and Metabolism Research Institute of Tehran University of Medical Sciences)

Ebrahim‐Habibi, A., Kashani‐Amin, E., & Larijani, B. A. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00706-x

Design of Pill Filming System and Automatic Pill Classification SystemPreprint

Lee, J., Kwon, S. Y., Kim, J., & Kim, K. G. (2021) · Research Square · doi:10.21203/rs.3.rs-487369/v1

Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment

Abolhassani, H., Bashiri, G., Montazeri, M., Kouchakzadeh, H., Shojaosadati, S. A., & Siadat, S. E. R. (2021) · Springer eBooks · doi:10.1007/978-981-16-3108-5_2

Design and Computational Analysis of a Chimeric Avian Influenza Antigen: A Yeast-displayed, Universal and Cross-protective Vaccine CandidatePreprint

Mohammadi, E., Pirkhezranian, Z., Dashti, S., Saedi, N., & Sekhavati, M. H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.05.459052

COVID-19 drug candidate pipeline, an overview

Sugiyama, H. (2021) · Folia Pharmacologica Japonica · doi:10.1254/fpj.21043

Reprofiling of Octogenarian Antiviral Agent: A New Avenue Venture to Discover Viral Infection

Farhana, N., Ahmed, M. G., Iqbal, M. A., D’Souza, N. G., Makuttan, S., Aggarwal, N. N., & Rahamanulla, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102825

Drug repositioning for immunotherapy in breast cancer using single-cell and spatial transcriptomics analysisPreprint

Mohammadi, E., Jin, H., Zhang, C., Shafizade, N., Dashti, S., Lam, S., Tahmoorespur, M., Mardinoğlu, A., & Sekhavati, M. H. (2022) · medRxiv · doi:10.1101/2022.11.18.22282496

Transformation in Health Sector During Pandemic by Photonics Devices

Ahlawat, J., Chaudhary, A., & Bhatia, D. (2023) · Signals and communication technology · doi:10.1007/978-3-031-19752-9_10

Exploring the Link Between Malaria and COVID-19

Arslan, O. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-20537-8_14

Drug Repositioning Using Genome-wide Screening and Systems Biology Approaches and Applications

(2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166037-00031

Integrating Computational Approaches from Non-synonymous Sequence Variations to Molecular Structure for Drug Repositioning Targeting the SARS-CoV-2 Spike Protein

Costa, L. S. C., Guedes, I. A., Fanticelli, H. C., Nicolas, M. F., & Dardenne, L. E. (2024) · Computer-aided drug discovery and design · doi:10.1007/978-3-031-69162-1_8

Neurotoxic Implications of Human Coronaviruses in Neurodegenerative Diseases: A Perspective from Amyloid Aggregation

Nguyen, T. H. V., Ferrón, F., & Murakami, K. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00153

Nanoparticles and bioactive materials against COVID-19 and its variants: Hints from a computational-materials design perspective

de Castro, A. A., de Assis, L. C., Appel, R. J. C., da Cunha, E. F. F., Nepovimová, E., Kuča, K., Ramalho, T. C., & Porta, F. A. L. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111046

Agentic AI for Drug Prescription: Machine Learning Models for Intelligent Healthcare Decision Support

Ibrahim, R. M., Mohammed, T. J., & Alsaidi, S. A. A. A. (2026) · Lecture notes in networks and systems · doi:10.1007/978-3-032-15806-2_21

Psychotropic Drugs: A Promising Non‐Antibiotic Agent to Combat Multi‐Drug‐Resistant Microorganisms

Singh, I. P., Singh, H., Sharma, D., Keshri, A., Gaurav, N., Dhakad, M. S., & Beg, M. M. A. (2026) · Drug Development Research · doi:10.1002/ddr.70380

DRUG REPOSITIONING FOR THERAPY OF COVID-19

Druzhilovskiy, D. S., Савосина, П. И., Гомазков, О. А., Sobolev, B. N., Veselovsky, A. V., Tarasova, O. A., Biziukova, N. Y., Ионов, Н. С., Ivanov, S. M., Rudik, A. V., et al. (2021) · BIOTECHNOLOGY STATE OF THE ART AND PERSPECTIVES · doi:10.37747/2312-640x-2021-19-209-211

In Silico Drug Repositioning for COVID-19: Progress and Challenges

Kumar, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_24 · Cited by 1 · see citing works

Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review)

Nițulescu, G. M., Păunescu, H., Moschos, S. A., Petrakis, D., Nițulescu, G., Ion, D., Spandidos, D. A., Νikolouzakis, Τ. Κ., Drakoulis, N., & Tsatsakis, A. M. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4608 · Cited by 131 · see citing works

Drug repurposing for COVID-19 therapy: challenges and opportunities

(2022) · International Multiconference on Bioinformatics of Genome Regulation and Structure / Systems Biology (BGRS/SB) · doi:10.18699/sbb-2022-198

Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches

Watashi, K. (2020) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2020.10.094 · Cited by 13 · see citing works